Difference between revisions of "Lysosomal Storage Disease"

From WikiVet English
Jump to navigation Jump to search
Line 42: Line 42:
  
 
===Pathophysiology===
 
===Pathophysiology===
 +
The clinical syndrome produced in each of the lysosomal storage disease results from the aberrant storage of metabolites within cells.  The storage diseases usually affect multiple organs but some, such as those that are caused by a defect in the myelin degradation pathway, may only cause neurological signs. 
  
 +
The mucopolysaccharidoses involve a failure to degrade glycosaminoglycans (major components of cartilage) and they often involve skeletal deformity.
 +
 +
==Diagnosis==
 +
===Clinical Signs===
 +
Many of the lysosomal storage diseases are associated with neurological signs.
 +
 +
===Laboratory Tests===
 +
Lysosonal storage disease often result in changes in leucocytic morphology which can be detected on a blood smear.
 +
{|cellpadding="10" cellspacing="0" border="1"
 +
| '''Disease'''
 +
| '''Finding on blood smear'''
 +
|-
 +
|
 +
|
 +
|}
 +
===Diagnostic Imaging===
 +
 +
===Other Tests===
 +
Since genetic techniques have become more widely available and easily performed, it is often possible to characterise the genetic defect directly by determining the sequence encoding enzymes thought to be deficient.  However, it should be remembered that several lysosomal storage diseases result from alterations in post-translational processes such as cellular trafficking.
 +
==Treatment==
 +
==Prognosis==
 +
==References==
 
[[Category:Liver - Storage Diseases]]
 
[[Category:Liver - Storage Diseases]]
 
[[Category:To_Do_-_James]]
 
[[Category:To_Do_-_James]]
 
[[Category:Dog]][[Category:Cat]]
 
[[Category:Dog]][[Category:Cat]]

Revision as of 11:20, 28 July 2010



Description

Lysosomal storage diseases occur due to inherited deficiencies of various lysosomal enzymes and this may be due to abnormalities in their synthesis, processing or cellular trafficking. The normal function of lysosomes is to degrade molecules within the cell and, when these chemical reactions are truncated by the absence of a key enzyme, the substrates of the reaction accumulate within the organelle. Since there is some redundancy in the pathways by which proteins are degraded, deficiencies in proteases do not usually result in clinical disease. Deficiencies in the nuclease enzymes are also not usually compatible with survival.

There are a large number of different lysosomal storage diseases in dogs and cats categorised according to the product which accumulates within cells. All of the storage disease are rare.

Classification

Class Defective Enzyme Name of Disease
Sphingolipidosis beta D gangliosidase

beta D hexosaminidase
beta D glucocerebrosidase
beta D galactocerebrosidase
Sphingomyelinase

GM1 Gangliosidosis

GM2 Gangliosidosis
Gaucher Disease
Krabbe Disease
Niemann-Pick Disease

Oligosaccharidosis
Mucopolysaccharidosis
Glycoproteinosis
Proteosis

Pathophysiology

The clinical syndrome produced in each of the lysosomal storage disease results from the aberrant storage of metabolites within cells. The storage diseases usually affect multiple organs but some, such as those that are caused by a defect in the myelin degradation pathway, may only cause neurological signs.

The mucopolysaccharidoses involve a failure to degrade glycosaminoglycans (major components of cartilage) and they often involve skeletal deformity.

Diagnosis

Clinical Signs

Many of the lysosomal storage diseases are associated with neurological signs.

Laboratory Tests

Lysosonal storage disease often result in changes in leucocytic morphology which can be detected on a blood smear.

Disease Finding on blood smear

Diagnostic Imaging

Other Tests

Since genetic techniques have become more widely available and easily performed, it is often possible to characterise the genetic defect directly by determining the sequence encoding enzymes thought to be deficient. However, it should be remembered that several lysosomal storage diseases result from alterations in post-translational processes such as cellular trafficking.

Treatment

Prognosis

References